clinical trial · NCT06176352
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Choroidal Neovascularization Secondary to Pathologic MyopiaFaricimabRanibizumabSham Procedure
brief summary
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
started
Mar 6, 2024
primary completion
Sep 11, 2025
completion
May 22, 2026
last updated
Jun 9, 2026
official title
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol